Background-Recently, the American Academy of Pediatrics updated guidance on lipid screening in childhood. Our objective was to examine recent distributions in concentrations of total cholesterol and low-density lipoprotein cholesterol among US children and adolescents and to estimate the prevalence of adolescents who are potentially eligible for pharmacological treatment for elevated concentrations of low-density lipoprotein cholesterol. Methods and Results-We used data from the National Health and Nutrition Examination Survey 1999 to 2006 for participants 6 to 17 years of age. The mean concentration for low-density lipoprotein cholesterol for participants 12 to 17 years of age was 90.2 mg/dL (nϭ2724), and the mean concentration of total cholesterol among participants 6 to 17 years of age was 163.0 mg/dL (nϭ9868). Depending on the cut points used, an elevated concentration of low-density lipoprotein cholesterol was noted for 5.2% to 6.6% of participants and an elevated concentration of total cholesterol for 9.6% to 10.7%. Approximately 0.8% of adolescents 12 to 17 years of age were potentially eligible for pharmacological treatment for elevated concentrations of low-density lipoprotein cholesterol. Conclusion-Given current guidelines, only a small percentage of US adolescents may need pharmacological treatment for elevated concentrations of low-density lipoprotein cholesterol.
T he roots of coronary heart disease herald back to childhood. Autopsy studies have demonstrated the presence of early lesions of coronary heart disease in the heart vessels of children and adolescents. 1 Furthermore, the presence of these changes correlated with known risk factors for cardiovascular disease, including concentrations of low-density lipoprotein cholesterol and total cholesterol. 2, 3 In addition, concentrations of low-density lipoprotein cholesterol predict subclinical atherosclerosis as determined by carotid intima-media thickness in adults. 4, 5 In recognition of the role of dyslipidemia in the early genesis of coronary heart disease, the American Academy of Pediatrics (AAP) recently released a report on lipid screening in childhood. 6 
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In that report, thresholds for defining hypercholesterolemia and elevated low-density lipoprotein cholesterol were summarized. One set of values were derived from a report from the National Cholesterol Education Program (NCEP) in 1992. Another set of values were derived from data from the Lipid Research Clinics Prevalence Study. Previous publications have provided important information about lipid concentra-tions in children and adolescents. [7] [8] [9] [10] [11] [12] [13] [14] However, much of that information is Ͼ10 years old. Therefore, our objective was to provide updated information about concentrations of lowdensity lipoprotein cholesterol and total cholesterol in children and adolescents in the United States.
Methods
We used data from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2006. During each consecutive 2-year cycle from 1999 through 2006, a national sample was recruited using a multistage, stratified sampling design. The surveys were designed to produce results representative of the civilian, noninstitutionalized US population. Participants were interviewed at home and were invited to attend a mobile examination center, where they were asked to complete additional questionnaires, undergo various examinations, and provide a blood sample. The surveys received human subject approval. Parental permission to allow a child to participate in the survey was obtained, as well as assent from children and adolescents 7 to 17 years of age. Participants Ն18 years of age were asked to sign an informed consent form. Details about the survey may be found elsewhere. 15 Measurements of concentrations of total serum cholesterol were conducted for participants Ն3 years of age for NHANES 1999 to 2004 Using the approach presented in the AAP report, we estimated the percentage of adolescents 12 to 17 years of age whose elevated concentration of low-density lipoprotein cholesterol potentially qualified them for pharmacological treatment. 6 The AAP uses 3 thresholds for elevated concentrations of low-density lipoprotein cholesterol to determine the need for pharmacological management of the dyslipidemia. If a patient does not have a risk factor (obesity, hypertension, cigarette smoking, family history of premature cardiovascular disease, or diabetes mellitus), pharmacological management can be considered when concentrations of low-density lipoprotein cholesterol exceed 190 mg/dL. In the presence of risk factors (obesity, hypertension, cigarette smoking, or family history of premature cardiovascular disease), pharmacological management can be considered when concentrations of low-density lipoprotein cholesterol exceed 160 mg/dL. In the presence of diabetes mellitus, pharmacological management can be considered when concentrations of low-density lipoprotein cholesterol equal or exceed 130 mg/dL.
Obesity was defined as a body mass index Ն95th percentile determined from the 2000 Centers for Disease Control and Prevention Growth Charts. 18 The recommendations of the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents were used to define hypertension. 19 Concentrations of cotinine were used to establish smoking status. A concentration Ͼ10 ng/mL was considered smoking. 20 Participants who had a fasting plasma concentration of glucose Ն126 mg/dL or reported using insulin or oral hypoglycemic agents were classified as having diabetes. Demographic covariates included in the analyses were age, sex, race, or ethnicity (white, black, Mexican American, other).
The main analyses include data from NHANES 1999 to 2006. Generally, analyses involving low-density lipoprotein cholesterol were limited to participants 12 to 17 years of age and analyses involving total cholesterol to those 6 to 17 years of age. In addition, we analyzed data for NHANES 1999 to 2004 to provide estimates of mean concentrations of total cholesterol for participants as young as 3 years of age and as old as 19 years of age and to make comparisons with previously published information concerning concentrations of total cholesterol and lowdensity lipoprotein cholesterol from NHANES III (1988 to 1994). We calculated means and percentages with elevated concentrations of lipids. For race-or ethnic-specific estimates, we present results for only the 3 major groups (whites, blacks, Mexican Americans). Differences in proportions and means were tested with 2 tests and t tests, respectively. Multiple linear regression analysis was conducted to examine the statistical significance of the effects of age, gender, and ethnicity on concentrations of lipids. Log-binomial regression analysis was used to examine the effects of age, gender, and ethnicity on the prevalence of elevated concentrations of lipids. In regression models, age was treated a continuous variable for analyses involving participants 12 to 17 years of age and was dichotomized for analyses involving participants 6 to 17 years of age (6 to 11 and 12 to 17 years of age). Software for the Statistical Analysis of Correlated Data (SUDAAN) was used for the analyses to account for the complex sampling design.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Of the 7180 participants 12 to 17 years of age who participated in NHANES 1999 to 2006, 2778 were part of the fasting subsample. Values of low-density lipoprotein cholesterol were available for 2724 of them. Participants with a value for low-density lipoprotein cholesterol were 0.7 years younger (Pϭ0.048). However, no significant differences in the percentage of participants who were male or white were present. Of the 11714 participants 6 to 17 years of age who attended the mobile examination center, 9868 had a value for total cholesterol. Participants with a value for total cholesterol were 1.3 years older (PϽ0.001). However, no significant differences in the percentage of participants who were male or white were present.
The mean concentration of low-density lipoprotein cholesterol among adolescents 12 to 17 years of age was 90.2 mg/dL ( Table 1 ). The results of a multiple linear regression model that included age, gender, ethnicity, and survey cycle showed that none of the demographic variables were significant predictors of concentrations of low-density lipoprotein cholesterol.
The mean concentration of total cholesterol among children and adolescents 6 to 17 years of age was 163.0 mg/dL. Results from the multiple linear regression analysis indicated that concentrations of total cholesterol were 6.2 mg/dL lower among participants 12 to 17 years of age than among those 6 to 11 years of age (PϽ0.001) and 3.6 mg/dL higher among girls than boys (PϽ0.001). Furthermore, concentrations of total cholesterol were 2.6 mg/dL higher among blacks than whites (Pϭ0.006) and 1.9 mg/dL lower among Mexican Americans than whites (Pϭ0.022). Mean concentrations of total cholesterol plotted by individual year of age for boys and girls participating in NHANES 1999 to 2004 suggest that the higher concentrations among girls start to emerge around 14 years of age (Figure) .
Percentiles for the concentrations of low-density lipoprotein cholesterol by demographic variables are shown in Table  2 , and percentiles for adolescents with a body mass index
Ͻ85th percentile are shown in Table 3 . Among participants with a body mass index Ͻ85th percentile, the median concentration of low-density lipoprotein cholesterol was Ϸ3 mg/dL lower than the median for all participants.
When Lipid Research Clinics Prevalence Study cut points were used, 5.2% of adolescents 12 to 17 years of age had an elevated concentration of low-density lipoprotein cholesterol, and 10.7% of participants 6 to 17 years of age had hypercholesterolemia ( Table 4 ). The results of the log-binomial analysis that included age, gender, ethnicity, and survey cycle showed no significant effects of the demographic variables on elevated concentrations of lowdensity lipoprotein cholesterol.
Compared with participants 6 to 11 years of age, participants 12 to 17 years of age had a lower prevalence of hypercholesterolemia (PϽ0.001). The prevalence of hypercholesterolemia was higher among boys than girls (Pϭ0.009) and higher among blacks than whites (Pϭ0.026).
The use of the NCEP cut points resulted in a somewhat higher prevalence of elevated concentrations of low-density lipoprotein cholesterol but a slightly lower prevalence of hypercholesterolemia (Table 5 ). Whereas the analyses based on the Lipid Research Clinics Prevalence Study cut points resulted in a higher prevalence of elevated concentrations of total cholesterol for boys than girls, the analyses based on the NCEP cut points yielded the opposite pattern. No statistically significant age, gender, or ethnic differences in the prevalence of elevated concentrations of low-density lipoprotein cholesterol were found.
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to 11 years of age. Blacks had a higher prevalence than whites (Pϭ0.016). No statistically significant differences were noted between boys and girls. Using the recommendations for pharmacological treatment of elevated concentrations of low-density lipoprotein cholesterol issued by the AAP, we found that Ϸ0.8% of adolescents 12 to 17 years of age were eligible for treatment. Because of the small magnitude of these percentages, detailed analyses for possible determinants were not feasible. Of the 26 adolescents who qualified for pharmacological treatment, 11 had a concentration Ͼ190 mg/dL (4 also had at least 1 risk factor, and 1 participant had a risk factor and diabetes), and 15 had at least 1 risk factor and a concentration Ͼ160 mg/dL. Only 1 participant 16 years of age reported using a cholesterol-lowering medication, in this case cholestyramine.
Discussion
The recent lipid screening recommendations issued by the AAP have drawn new attention to the importance of healthy lipid concentrations in children and adolescents. Our analysis of recent national data from the United States indicates that, depending on the cut points used, 5.2% to 6.6% of adolescents 12 to 17 years of age had elevated concentrations of low-density lipoprotein cholesterol. Furthermore, 0.8% of such adolescents would qualify for lipid-lowering treatment based on the AAP guidelines.
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data, whereas those for boys differ somewhat. Limiting the analysis to those who were not overweight or obese reduced the NHANES medians by a few milligrams per deciliter. NHANES data have demonstrated clear decreases in concentrations of total cholesterol among adolescents 12 to 17 years of age in the United States from 1966 to 1970 to 1988 to 1994. 13 During this same period, marked increases in childhood obesity occurred in the United States. An unfavorable effect of obesity on concentrations of lipids in children has been demonstrated. 21 Beside the possible effects of temporal trends, differences in characteristics of the study populations and laboratory methods further complicate comparisons between the 2 sets of data. Several major studies, including the Muscatine Study, Lipid Research Clinics Prevalence Study, Bogalusa Heart Study, and NHANES, have provided important information about concentrations of lipids in children and adolescents in the United States. [7] [8] [9] [10] [11] [12] [13] [14] These studies have yielded important information about age, gender, and ethnic differences in concentrations of lipids. In addition, critical insights into the tracking of concentrations of lipids have been gleaned from these studies. [22] [23] [24] Data from NHANES III (1988 to 1994) provided some of the most detailed information about concentrations of lipids in children and adolescents in the United States. 13 The authors provided means and various percentiles of lipid distributions but did not provide estimates of the prevalence of elevated concentrations of lipids. The 90th percentile for participants 4 to 19 years of age in that survey was 200 mg/dL, which is the same as in NHANES 1999 to 2004. Consistent with the findings from NHANES III, we also observed that concentrations of total cholesterol peaked around 8 to 10 years of age. No age-related differences in concentrations of total cholesterol were reported from the Muscatine Study. 7 In NHANES III, concentrations of total cholesterol were higher in female than male participants. 13 In addition, [11] [12] [13] 25 but not in other studies. 7, 9 Our results showing that concentrations of total cholesterol were higher among black children and adolescents than white children and adolescents are consistent with the results from previous studies. 8, 13, 25 In NHANES III, concentrations of total cholesterol were 6 mg/dL higher among black children and adolescents 4 to 19 years of age than white children and adolescents. 13 26 it appears that little change in mean concentrations of total cholesterol took place over a period of Ϸ10 to 11 years. This stands in contrast to the 7-mg/dL decline that occurred among adolescents 12 to 17 years of age from 1966 to 1970 to 1988 to 1994.
For participants 12 to 19 years of age, mean concentrations of low-density lipoprotein cholesterol were 95 mg/dL (SE, 1.6 mg/dL) in NHANES III 13 and 94 mg/dL (SE, 0.8 mg/dL) in NHANES 1999 to 2004. For boys 12 to 19 years of age, mean concentrations were 91 mg/dL (SE, 2.1 mg/dL) in NHANES III and 94 mg/dL (SE, 1.3 mg/dL) in NHANES 1999 to 2004. For girls 12 to 19 years of age, mean concentrations were 99 mg/dL (SE, 2.4 mg/dL) in NHANES III and 93 mg/dL (SE, 1.0 mg/dL) in NHANES 1999 to 2004. Thus, little change in mean concentrations of low-density lipoprotein cholesterol occurred during the period covered by 2 surveys, although the data suggest that concentrations increased in boys and decreased in girls.
Because information about a family history of cardiovascular disease was not collected for participants Ͻ20 years of age, we were unable to estimate precisely the prevalence of children and adolescents who were potentially eligible for pharmacological treatment. Although our estimate of Ϸ0.8% is an underestimate as a result, it is not likely to be substantially higher. In addition, larger sample sizes would have allowed more detailed analyses of lipid concentrations by combinations of demographic variables. About 5.2% to 6.6% of adolescents 12 to 17 years of age had elevated concentrations of low-density lipoprotein cholesterol, and 9.6% to 10.7% of children and adolescents 6 to 17 years of age had elevated concentrations of total cholesterol. An estimated 0.8% of children and adolescents 12 to 17 years of age qualified for pharmacological treatment to lower concentrations of low-density lipoprotein cholesterol. According to population projections for the US population in 2008, Ϸ25 million people were 12 to 17 years of age. Thus, a percentage of Ϸ0.8% of adolescents who might be eligible for pharmacological treatment would represent Ϸ200 000 adolescents 12 to 17 years of age. NHANES data from 1999 to 2006 provide an updated picture of the state of affairs regarding concentrations of low-density lipoprotein cholesterol and total cholesterol in children and adolescents in the United States and the size of the potential pool of children and adolescents who may be eligible for pharmacological treatment for elevated concentrations of low-density lipoprotein cholesterol.
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